Clinical trial NCT01843127: A Study to Evaluate the Effect of Ranolazine on Postprandial Glucagon in Subjects With Type 2 Diabetes.
Official title: A Phase 1, Randomized, Single-blind, Placebo-controlled, Multiple-dose, Two-sequence, Cross-over Study to Evaluate the Effect of Ranolazine on Glucagon Secretion in Subjects With Type 2 Diabetes Mellitus, Followed by An Open-label, Single Dose, Exenatide Active-control Period
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Type 2 Diabetes Mellitus
Lead sponsor: Gilead Sciences
Sponsor class: INDUSTRY
First posted: 2013-04-30
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: To explore the mechanism of action of ranolazine as a potential treatment for type 2 diabetes mellitus (T2DM).


Eligibility criteria: Inclusion Criteria:

* Males and females, 18 to 65 years old, inclusive
* Documented history of T2DM for ≥5 years
* Body mass index (BMI) 20.0 to 40.0 kg/m2, inclusive, at Screening
* Stable treatment (≥ 12 weeks) with metformin alone, a sulfonylurea alone, a meglitinide alone, or a combination of metformin with either a sulfonylurea or a meglitinide
* HbA1c ≥ 7.0% and ≤ 10.5%, inclusive, at Screening
* Fasting glucose within specific ranges, at Screening and after 14 +/-2 days of wash-out from prior oral anti-diabetic agents
* Fasting serum C-peptide ≥0.8 ng/mL, at Screening
* Estimated glomerular filtration rate (eGFR)≥60 mL/min/1.73 m2
* Ability and willingness to comply with all study procedures during the course of the study, including washout from oral anti-diabetic (OAD) agents approximately 2 weeks prior to Day -2 admission
* Females of childbearing potential must have a negative pregnancy test at Screening and on Day -2 admission and must agree to use highly effective contraception methods from Screening throughout study participation and for 14 days following the last dose of study drug.

Exclusion Criteria:

* History of type 1 diabetes mellitus or secondary forms of diabetes
* History of acute diabetes complications
* Recent or significant heart conditions
* Uncontrolled hypertension
* QTc interval \> 500 msec by ECG at Screening or on Day -2 admission, a personal or family history of QTc prolongation, congenital long QT syndrome, or use of drugs that prolong the QTc interval, such as Class Ia or Class III antiarrhythmic agents, erythromycin, and certain antipsychotics (eg, ziprasidone)
* History of severe GI disease (e.g., gastroparesis)
* History of pancreatitis (acute or chronic)
* Current consumption of \> 14 alcoholic drinks per week, or more than 4 alcoholic drinks on any one day
* Current regular use of tobacco- or nicotine-containing products in excess of 10 cigarettes per day or equivalent
* History of substance abuse within 12 months prior to Screening
* Significant hepatic disease, including, but not limited to, chronic active hepatitis and liver cirrhosis (Child-Pugh Class A, B, or C)
* History of malignancy within 5 years prior to Screening
* Significant thyroid disease
* Treatment with selected medications, as indicated in the protocol
* Prior treatment with open-label ranolazine or known hypersensitivity or intolerance to ranolazine or its excipients
* Known hypersensitivity or intolerance to GLP-1 mimetics
* Known hypersensitivity or intolerance to acetaminophen
* Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) \> 2.5 X upper limit of normal (ULN)
* Total Bilirubin (TB) \> 2 mg/dL
* Hemoglobin \< 12 g/dL (for males) or \< 11 g/dL (for females)
* Positive for hepatitis B surface antigen
* Positive for anti-hepatitis C virus antibody
* Positive for human immunodeficiency virus-1 (HIV-1) antibody
* Positive urine drug screen
* Positive alcohol test
* Donation of blood or blood products to a blood bank, blood transfusion, or participation in a clinical study requiring withdrawal of \> 500 mL of blood during the 6 weeks prior to Screening
* Females who are pregnant or breastfeeding
* Other condition(s) that, in the opinion of the investigator, would compromise the safety of the subject, would prevent compliance with the study protocol, or would compromise the quality of the clinical study.

Primary outcomes:
measure: Area under the concentration-time curve (AUC) of plasma glucagon during the standard meal test (SMT)
timeFrame: Days 5, 10, and 14
Secondary outcomes:
measure: Plasma glucose, serum insulin, and serum C-peptide AUCs during the SMT
timeFrame: Days 5, 10, and 14
measure: Collapse under Acetaminophen PK
timeFrame: Days 5 and 10
measure: Area under the plasma acetaminophen concentration-time curve from time 0 to 240 min (AUC0-240 min)
timeFrame: Days 5 and 10
measure: Collapse all under ranolazine pharmacokinetics (PK)
timeFrame: Days 5 and 10
measure: Trough plasma ranolazine concentrations (Ctrough)
timeFrame: Days 5 and 10
measure: Average plasma ranolazine concentration during a dosing interval at steady state (Css,ave)
timeFrame: Days 5 and 10
measure: Area under the plasma ranolazine concentration-time curve over dosing interval (AUCtau)
timeFrame: Days 5 and 10
measure: Apparent elimination half-life (t1/2) of ranolazine
timeFrame: Days 5 and 10
measure: Adverse events, physical examinations, clinical laboratory determinations, electrocardiograms (ECG), and vital sign assessments.
timeFrame: From Screening to 7 days after the final dose
Other outcomes:
Locations:
city: Chula Vista
country: United States
facility: Profil Institute for Clinical Research, Inc.
state: California
city: Miami
country: United States
facility: SeaView Research, Inc
state: Florida
city: Orlando
country: United States
facility: Translational Research Institute-Florida Hospital
state: Florida
Study officials:
References: